Open-label and randomized clinical trials that have examined the effects of tDCS to target negative symptoms of schizophrenia have placed the anode over the left DLPFC and the cathode over the right DLPFC or the right supraorbital region or placed it extra-cephalically (221, 227–229). A meta-analysis concluded that tDCS treatment is beneficial for improving negative symptom domain indications (211). There has been direct support for the safety of tDCS in human clinical trials with the most often reported side-effect of mild skin erythema, itching, tingling and burning under the electrode placement as well as temporary headache and dizziness which resolves after stimulation (218, 220).